Medical big data has been done for more than a decade, but now a lot of information in various hospitals is completely silent there. "If the 20th century is the era when oil is king, the 21st century is the era when data is king." Recently, at the International Biomedical and Medical Big Data Symposium hosted by the Beijing Association for Science and Technology, experts at the conference said. However, in the opinion of experts, the "sword" of China's medical big data has been blunt for more than a decade, and China's development in medical big data is not optimistic. “Medical big data has been done for more than ten years, but now a lot of information in various hospitals is completely silent there.†Wei Yun, professor of the Oriental Hospital of Beijing University of Chinese Medicine and director of the Information Management Department, said that the utilization rate of medical big data in China is still Too low. Will medical big data break out in silence or die in silence? This has created new challenges for China's biomedical and medical fields. New opportunities for healthy China Since 1980, the US Department of Health and Welfare has issued a health plan every ten years, with a core focus on improving the health of all citizens. The Ministry of Health of China also officially proposed the "Healthy China 2020" strategy at the "2008 National Health Work Conference". Among them, big data brings unprecedented opportunities. Liu Longjian, director of the Department of Environmental and Occupational Health at the Drexel University School of Public Health in Pennsylvania, said that big data can help to study the health characteristics of different populations, discover new diseases, and control global infectious diseases. Li Wei, director of the Department of Medical Statistics at the National Cardiovascular Center, said that big data has also brought good news to the safety evaluation of medical devices. The State Food and Drug Administration stipulates that medical devices must evaluate their safety and evaluate the effectiveness. “At the moment, we usually only evaluate its effectiveness. Because the number of patients participating in a clinical trial is very limited, it is difficult to assess the safety risk of low incidence.†Li Wei said that the emergence of big data makes security Evaluation is possible. “With massive data, we can see all the patients who have used this product.†Not only that, big data has also brought dawn to the development of new drugs. "Domestic and domestic pharmaceutical companies are now facing huge research and development difficulties, and these dilemmas, such as clinical experimental data problems, can be solved with big data." Zhang Biyu, general manager of An Biqi (Tianjin) Biotechnology Co., Ltd. said. "silent" information sharing is difficult Wei Yun is a doctor in blood immunization. He is also the director of the Beijing TCM Quality Control Center and the chairman of the Information Professional Committee of the Beijing Association of Integrative Medicine. Her work has been related to data information for the past 15 years. For this reason, she saw the worrying “silence†of medical big data for more than a decade. In Wei Yun's view, such "silence" is caused by low data utilization and lack of sharing mechanisms. "Is there any use of these silent data? Yes! However, the unit that needs the data cannot get the data, and the unit that has the data needs to be kept secret. This is a contradiction." Wei Yun said with emotion. She said that it is urgent to establish a mechanism to break the barriers to sharing. "We can't ask others to share, nor can we let the government introduce policies to promote sharing. However, the work of the past few years has made me realize that we can do research and development, do projects, and do projects together. There is a lot of demand." Just a few days ago, Liu Shiping, chief scientist of the Center for Financial Technology of the Chinese Academy of Sciences, was invited by Shanghai Jiaotong University to give a report on medical big data. After talking with experts from 12 affiliated hospitals of Shanghai Jiaotong University, he found that they had a strong desire to collect and share data. For drug development companies, data sharing is even more important. "In this regard, we still have to learn from the United States. Companies in the United States have integrated clinical data and analyzed better recommendations." Zhang Wenzhao said. Medical data like block "honeycomb" For the medical field, 1.3 billion people are a valuable repository of evidence. “As a country of evidence, there are many patients in China, just like having a vast wheat field. But to turn the flour into bread on the table, we need a flour processing platform to use technology to build a platform for data collection, processing, analysis and statistics. Tian Xinping, chief physician of Peking Union Medical College Hospital, said. At present, although China has a large amount of big data, it lacks effective processing and analysis capabilities. The biggest interference factor is the inconsistency of data standards. In the opinion of experts, China's medical big data is like a large piece of “honeycomb coalâ€. "There is no unified standard for data collection and organization. The same product line is open, but different product lines are not feasible." Liu Shiping said. Wei Yun said that the standard of medical dataization in China can be described as "a hundred flowers bloom." “Every hospital's informatization work involves dozens of manufacturers. Each manufacturer's data, standards, collection and storage are different. Therefore, even in a hospital, there will be many isolated islands, not to mention the entire medical industry . "Wei Yun said. "The standards and interfaces of information systems in different hospitals are different, which is one of the reasons for low utilization and difficulty in sharing." Li Wei said. Not only that, but the variety of data types also poses challenges for the development and application of data standards. "Most of the data we can process before is structured text data, but it is difficult to deal with unstructured audio and video data," Liu said.
We're Professional Supplier Extract Powder manufacturers and suppliers in China specialized in providing high-quality products at low price. We warmly welcome you to buy or wholesale bulk Supplier Extract Powder for sale here from our factory. For a free sample, contact us now.
Supplier Extract Powder,Supplier Extract ,Supplier Powder Manufacturer in China Shaanxi Kang New Pharmaceutical co., Ltd. , https://www.bio-pharmacies.com